Literature DB >> 9890708

Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.

A M Vázquez1, A Pérez, A M Hernández, A Macías, M Alfonso, G Bombino, R Pérez.   

Abstract

An IgM monoclonal antibody (MAb), named P3, has the characteristic to react specifically with a broad battery of N-glycolyl containing-gangliosides and with antigens expressed on breast tumors. When this MAb was administered alone in syngeneic mice, an specific IgG anti-idiotypic antibody (Ab2) response was induced, this Ab2 response was increased when P3 MAb was injected coupled to a carrier protein and in the presence of Freund's adjuvant. Spleen cells from these mice were used in somatic-cell hybridization experiments, using the murine myeloma cell line P3-X63-Ag8.653 as fusion partner. Five Ab2 MAbs specific to P3 MAb were selected. These IgG1 Ab2 MAbs were able to block the binding of P3 MAb to GM3(NeuGc) ganglioside and to a human breast carcinoma cell line. Cross-blocking experiments demonstrated that these Ab2 MAbs are recognizing the same or very close sites on the Abl MAb. The five Ab2 MAbs were injected into syngeneic mice and four of them produced strong anti-anti-idiotypic antibody (Ab3) response. While these Ab2 MAbs were unable to generate Ab3 antibodies with the same antigenic specificity than P3 MAb, three of them induced antibodies bearing P3 MAb idiotopes (Ag-Id+ Ab3). These results demonstrated that these Ab2 MAbs are not "internal image" antibodies, but they could define "regulatory idiotopes."

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9890708     DOI: 10.1089/hyb.1998.17.527

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  16 in total

1.  Immunopotentiating properties of a multispecific α-anti-idiotype antibody.

Authors:  Tays Hernández; Cristina Mateo de Acosta; Rolando Pérez
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.

Authors:  Adam Yagui-Beltrán; Lisa M Coussens; David M Jablons
Journal:  US Oncol       Date:  2009

Review 3.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 4.  Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.

Authors:  Ronan J Kelly; James L Gulley; Giuseppe Giaccone
Journal:  Clin Lung Cancer       Date:  2010-07-01       Impact factor: 4.785

Review 5.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

6.  Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer.

Authors:  Valeria I Segatori; Ana M Vazquez; Daniel E Gomez; Mariano R Gabri; Daniel F Alonso
Journal:  Front Oncol       Date:  2012-11-08       Impact factor: 6.244

7.  Physicochemical and biological characterization of 1E10 anti-idiotype vaccine.

Authors:  Yoan J Machado; Yamilet Rabasa; Raquel Montesinos; José Cremata; Vladimir Besada; Dasha Fuentes; Adolfo Castillo; Kathya R de la Luz; Ana M Vázquez; Martin Himly
Journal:  BMC Biotechnol       Date:  2011-11-22       Impact factor: 2.563

8.  Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer.

Authors:  Jorge L Soriano; Noyde Batista; Eduardo Santiesteban; Mayté Lima; Joaquín González; Robin García; Yohanka Zarza; María V López; Myriam Rodríguez; Jorge L Loys; Narciso Montejo; Frank Aguirre; Amparo Macías; Ana M Vázquez
Journal:  Int J Breast Cancer       Date:  2011-07-14

9.  Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.

Authors:  Ana M Vázquez; Ana M Hernández; Amparo Macías; Enrique Montero; Daniel E Gómez; Daniel F Alonso; Mariano R Gabri; Roberto E Gómez
Journal:  Front Oncol       Date:  2012-10-23       Impact factor: 6.244

10.  Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

Authors:  Ana M H Vázquez; Nely Rodrèguez-Zhurbenko; Ana M V López
Journal:  Front Oncol       Date:  2012-11-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.